|
|
Is protracted low-dose temozolomide
feasible in glioma patients?
A. Tosoni, MD, G.
Cavallo, MD, M. Ermani, MD, L. Scopece, MD,
E. Franceschi, MD, C. Ghimenton, MD, M.
Gardiman, MD, L. Pasetto, MD, V. Blatt, DM
and A. A. Brandes, MD
From the Departments of Medical
Oncology (A.T., L.P., V.B., A.A.B.), Neurological Sciences (E.M.), and
Pathology (M.G.), University Hospital of Padova; Department of Medical
Oncology (G.C., L.S., E.F.), Bellaria Hospital, Bologna; and
Department of Pathology (C.G.), Verona Hospital, Italy.
Address correspondence and reprint requests to Dr. Alba A. Brandes,
Department of Medical Oncology, Azienda Ospedale-Universitą, Ospedale
Busonera, Via Gattamelata 64, 35100 Padova, Italy; e-mail: aabrandes@unipd.it.
|
|
|
The authors investigated the safety of 75
mg/m2 temozolomide for 21 days every 28 days in
glioma patients.
This schedule could lead to DNA
repair enzyme O6-alkylguanine-DNA alkyltransferase depletion,
contributing to overcoming drug resistance.
Although Phase III studies are
forthcoming, no data are available on the long-term
toxicity of temozolomide, which, in this series, incurred
prolonged, cumulative lymphopenia, which leads to a high
incidence of infections.
|
